<?xml version="1.0" encoding="UTF-8"?>
<p>A total of 71 patients aged ≥55 years (
 <italic>n</italic> = 61) or &lt;55 years (
 <italic>n</italic> = 10) were enrolled: 66 patients with AML and five patients with MDS; 69 patients (
 <italic>n</italic> = 60/9, aged ≥55/&lt;55 years) were treated and included in the full analysis set; two patients were enrolled, but not treated. Of 69 patients who were treated, six (8.7%) completed treatment and 63 (91.3%) patients discontinued treatment (Supporting Information 
 <xref rid="ajh25238-supitem-0001" ref-type="supplementary-material">Figure S1</xref>). The main reasons for discontinuations from study treatments were: insufficient clinical response (
 <italic>n</italic> = 29; 42.0%) and "other” (
 <italic>n</italic> = 15; 21.7%), with the majority of "other” due to transplantation (
 <italic>n</italic> = 12/15); 11 (15.9%) patients permanently discontinued study treatments due to treatment‐related AEs, which included neutrophil count decreased and pneumonitis (related to daunorubicin and cytarabine); myocarditis (related to daunorubicin and glasdegib); intermittent elevated alanine aminotransferase (ALT) (related to daunorubicin, cytarabine and glasdegib); diarrhea (related to daunorubicin, cytarabine and glasdegib) and nausea in one patient; gastrointestinal bleeding and infectious enterocolitis in one patient; adenovirus infection; worsening muscle cramps; epigastric pain; atrial fibrillation; and elevated aspartate aminotransferase and ALT in one patient.
</p>
